Read more about Natco s partner Breckenridge Pharmaceutical receives USFDA approval for Everolimus Tablets on Business Standard. NATCO s partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks. The launch of 10 mg strength of the product is subject to confidential terms of a settlement and license agreement entered
Synopsis Breckenridge Pharmaceutical Inc (BPI) has received final approval for its abbreviated new drug application (ANDA) for Everolimus tablets from the US Food and Drug Administration (USFDA), Natco Pharma said in a regulatory filing.
Agencies
Natco s partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
Natco Pharma on Monday said its marketing partner Breckenridge Pharmaceutical Inc has received final approval from the US health regulator for cancer treatment drug Everolimus. The approved product is a generic for Afinitor. Breckenridge Pharmaceutical Inc (BPI) has received final approval for its abbreviated new drug application (ANDA) for Everolimus tablets from the US Food and Drug Administration (USFDA), Natco Pharma said in a regulatory filing.
Natco Pharma jumped 6.2% to Rs 884.35 after the company received final approval for everolimus tablets in the US market.Natco Pharma announced that its marketing partner, Breckenridge Pharmaceutical Inc. (BPI), has received final approval for its abbreviated new drug application (ANDA) for everolimus tablets (a generic version of Afinitor) from the US Food and Drug Administration (USFDA).
BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks. The launch of 10mg strength of the product is subject to confidential terms of a settlement and license agreement entered into with the owner of the Afinitor brand. The launch date of 10mg strength of the product will be announced at a later date.
NATCO receives final approval for Everolimus tablets for the US market
Posted On: 2021-03-07 22:25:27 (Time Zone: Arizona, USA)
Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has announced that its marketing partner, Breckenridge Pharmaceutical Inc. (BPI), has received final approval for its Abbreviated New Drug Application (ANDA) for Everolimus Tablets (generic for Afinitor®) from the U.S. Food and Drug Administration (USFDA).
NATCO s partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks. The launch of 10mg strength of the product is subject to confidential terms of a settlement and license agreement entered into with the owner of the Afinitor® brand. The launch date of 10mg strength of the product will be announced at a later date.
Breckenridge Announces Final Approval of its ANDA for Asenapine Sublingual Tablets, 5 mg Strength (generic for Saphris®)
News provided by
Share this article
Share this article
BERLIN, Conn., March 8, 2021 /PRNewswire/ Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Asenapine Sublingual Tablets in 5mg strength (generic for Saphris
®). Breckenridge plans to launch this strength immediately. Breckenridge previously launched the product s 2.5mg and 10mg strengths and will now market all three strengths. This product was developed in collaboration with MSN Laboratories Private Limited. According to industry sales data, Saphris